Search results
Showing 3451 to 3500 of 4090 results for patient
based on both cause and treatment lag; this would require large numbers of patients and would need to be multicentre, possibly involving...
reduce mortality from haemorrhage, which is the main cause of death in patients with major trauma. Point-of-care ROTEM and TEG are...
the cost of assessment while in hospital is particularly important for patients with dementia or delirium because early identification...
myeloma. This study should be a randomised multi-centre prospective trial for patients with newly diagnosed smouldering myeloma (as...
Read NICE's statement on modern slavery and human trafficking.
life (ideally employing a tool validated in idiopathic pulmonary fibrosis patients). Phase III trials should include a health economic...
water excretion. Clinical trials have not yet resolved whether in some patients, the use of low‑dose dopamine actually results in...
Deaths reports in 1999 and 2009 identified problems in fluid management in patients in the UK. A lack of consistency in prescribing and...
people. Hospital services have adapted to the growing population of older patients by introducing liaison services such as Frail Older...
It is well recognised that they have a poor quality of life (QoL). Most patients have adjuvant treatment, however their nutritional...
and cost effectiveness. The ideal sample size will be around 400 to 500 patients, and the primary outcome should be physical function...
effectiveness of the different solutions available. The trial should enrol patients in the community with a VAD. The protocol would need...
to induce remission in a first presentation of colonic Crohn's disease. Patients would be recruited once in remission and...
reduce pain and improve wound healing, and may prevent amputation in some patients. Initially achieved surgically, it is now most...
secondary care. These are costly for commissioners, cause unnecessary anxiety for patients and are a burden for secondary care. A...
quality standards is to make it clear what quality care is by providing patients and the public, health and social care professionals,...
NICE has developed a medtech innovation briefing (MIB) on narrow band imaging for Barrett’s oesophagus .
such as distress and beliefs about psoriasis. Tools that can be used by patients (as well as healthcare professionals) to assess disease...
indicates active airway inflammation, identifying non-responsiveness in treated patients may help demonstrate good asthma control with...
impact on bed occupancy rates. Current figures suggest that 22% of hospital patients are waiting for a social care assessment so that...
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
knowledge, the committee recommended that biopsies should be considered for patients with a single lung lesion to rule out primary lung...
underlying cause of RCSE, its duration and management. The majority, if not all patients with RCSE are managed in an ICU. There are no...
Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain (MIB238)
NICE has developed a medtech innovation briefing (MIB) on Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain .
Have your say on NICE's adoption of the new EQ-5D-5L value set
We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of life.
First NICE recommended treatment for uncontrolled generalised myasthenia gravis
We’ve recommended a new treatment called rozanolixizumab for some adults living with generalised myasthenia gravis (gMG) whose symptoms are not controlled by existing treatments.
Evidence summaries: new medicines – Interim process statement (PMG1)
This interim process statement sets out to guide the development of 'Evidence summaries: new medicines' (ESNMs). It provides an overview of the key process principles and describes all stages of the development of ESNMs
NICE has developed a medtech innovation briefing (MIB) on fasciotens for abdominal wall closure .
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.
November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.
committee were aware from cases highlighted by stakeholders that individual patients have reported having fewer seizures with these...
committee were aware from cases highlighted by stakeholders that individual patients have reported having fewer seizures with these...
Harmful sexual behaviour among children and young people (NG55)
This guideline covers children and young people who display harmful sexual behaviour, including those on remand or serving community or custodial sentences. It aims to ensure these problems don’t escalate and possibly lead to them being charged with a sexual offence. It also aims to ensure no-one is unnecessarily referred to specialist services.
without N-acetylcysteine.The committee did not consider it necessary for all patients being offered iodine-based contrast media to be...
Can risk of contrast-induced acute kidney injury be stratified by eGFR thresholds?
without N-acetylcysteine.The committee did not consider it necessary for all patients being offered iodine-based contrast media to be...
combination treatment with levothyroxine and liothyronine in small subgroups of patients. The committee were aware that some people...
Discontinued Reference number: GID-TA11124
NICE recommends life changing technology is rolled out to people with type 1 diabetes
Thousands of people with type 1 diabetes could be offered wearable technology to help them manage their condition following the publication of final draft guidance by NICE.
Child maltreatment: when to suspect maltreatment in under 18s (CG89)
This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help healthcare professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.
Discontinued Reference number: GID-TAG402
Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.
What is the clinical and cost effectiveness of preoperative optimisation clinics for older people?
evidence was identified comparing LMWH with UFH in this high-risk group of patients. The committee noted that people who take a vitamin...
evidence was identified comparing LMWH with UFH in this high-risk group of patients. The committee noted that people who take a vitamin...
evidence was identified comparing LMWH with UFH in this high-risk group of patients. The committee noted that people who take a vitamin...
Hypercholesterolaemia (primary), dyslipidaemia (mixed) - anacetrapib [ID1165]
Discontinued Reference number: GID-TA11175
Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]
Discontinued Reference number: GID-TA10702
This guideline covers assessing and treating bedwetting in people aged under 19. It aims to reduce bedwetting and the distress this causes by explaining what to ask in an assessment, what advice to provide, and which treatments are effective.
Discontinued Reference number: GID-TAG444
Recommendations will help organisations that evaluate new drugs establish whether their use will result in longer-term benefits for patients
In development Reference number: GID-MT591 Expected publication date: TBC